{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T23:16:27Z","timestamp":1721862987444},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,11,1]],"date-time":"1999-11-01T00:00:00Z","timestamp":941414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[1999,11]]},"DOI":"10.1016\/s1089-3261(05)70240-3","type":"journal-article","created":{"date-parts":[[2005,6,25]],"date-time":"2005-06-25T11:39:04Z","timestamp":1119699544000},"page":"811-826","source":"Crossref","is-referenced-by-count":18,"title":["COMBINATION TREATMENT WITH INTERFERON AND RIBAVIRIN FOR CHRONIC HEPATITIS C"],"prefix":"10.1016","volume":"3","author":[{"given":"Gary L.","family":"Davis","sequence":"first","affiliation":[]}],"member":"78","reference":[{"issue":"suppl","key":"10.1016\/S1089-3261(05)70240-3_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/hep.510260724","article-title":"Therapy of hepatitis C: Retreatment with alpha interferon","volume":"26","author":"Alberti","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib2","first-page":"216A","article-title":"IFN\u03b1-n3 or IFN\u03b1-n3 plus ribavirin in chronic hepatitis C resistant to other IFN\u03b1 treatments: Results of a randomized multicenter trial [abstract]","volume":"26","author":"Andreone","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib3","first-page":"372A","article-title":"Interferon-ribavirin combination is successful in eliminating hepatitis C virus in non-responders to interferon alone including patients with normal aminotransferases responders [abstract]","volume":"28","author":"Bacon","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib4","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1572-0241.1998.00702.x","article-title":"Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: An Italian multicenter, randomized, controlled, clinical study","volume":"93","author":"Barbaro","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2893.1997.00142.x","article-title":"Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: A randomized clinical trial","volume":"4","author":"Bellobouno","year":"1997","journal-title":"J Viral Hepat"},{"key":"10.1016\/S1089-3261(05)70240-3_bib6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/hep.510260236","article-title":"Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation","volume":"26","author":"Bizollon","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial","volume":"26","author":"Bodenheimer","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.510290124","article-title":"Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy","volume":"29","author":"Bonkovsky","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/00365549509032725","article-title":"Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: A pilot study","volume":"27","author":"Braconier","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/S1089-3261(05)70240-3_bib10","first-page":"367A","article-title":"Triple antiviral therapy for chronic hepatitis C in interferon alfa non-responders: A pilot randomized controlled study [abstract]","volume":"26","author":"Brillanti","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/0016-5085(94)90131-7","article-title":"A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C","volume":"107","author":"Brillanti","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib12","first-page":"395A","article-title":"A randomized controlled trial of leukocyte IFN alfa + ribavirin in HCV chronic hepatitis relapsing patients [abstract]","volume":"24","author":"Caremani","year":"1996","journal-title":"Hepatology"},{"issue":"suppl","key":"10.1016\/S1089-3261(05)70240-3_bib13","first-page":"8","article-title":"The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C","volume":"23","author":"Chemello","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib14","first-page":"192","article-title":"Should patients with chronic hepatitis C who relapse after interferon be retreated? [abstract]","volume":"26","author":"Craxi","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib15","series-title":"Clinical Applications of Ribavirin","first-page":"33","article-title":"Overview of ribavirin treatment of infection caused by RNA viruses","author":"Crumpacker","year":"1984"},{"issue":"suppl 1","key":"10.1016\/S1089-3261(05)70240-3_bib16","first-page":"49","article-title":"Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C","volume":"19","author":"Davis","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/S1089-3261(05)70240-3_bib17","first-page":"658","article-title":"Interferon treatment of cirrhotic patients with chronic hepatitis C: A logical intervention","volume":"89","author":"Davis","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"suppl","key":"10.1016\/S1089-3261(05)70240-3_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.510260721","article-title":"Factors predictive of a beneficial response to therapy of hepatitis C","volume":"26","author":"Davis","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib19","first-page":"390A","article-title":"Projecting the future healthcare burden from hepatitis C in the United States [abstract]","volume":"28","author":"Davis","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib20","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled study","volume":"321","author":"Davis","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/S1089-3261(05)70240-3_bib21","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"the International Hepatitis Interventional Therapy Group. Retreatment of relapse after interferon therapy for chronic hepatitis C: An international randomized controlled trial of interferon plus ribavirin vs interferon alone","volume":"339","author":"Davis","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S1089-3261(05)70240-3_bib22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.1840160307","article-title":"Pilot study of ribavirin therapy for chronic hepatitis C","volume":"16","author":"Di Bisceglie","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib23","first-page":"262A","article-title":"Final analysis of ribavirin and alpha-interferon for the treatment of hepatitis C infection after liver transplantation [abstract]","volume":"28","author":"Dodson","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib24","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V92.8.2983","article-title":"Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia [letter]","volume":"92","author":"Donada","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S1089-3261(05)70240-3_bib25","first-page":"1115","article-title":"Ribavirin in hepatitis C related cryoglobulinemia","volume":"25","author":"Durand","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","article-title":"Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study","volume":"25","author":"Dusheiko","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib27","first-page":"1222","article-title":"Combination treatment of alpha interferon 2b and ribavirin in chronic hepatitis C genotype 4 patients resistant to interferon therapy [abstract]","volume":"26","author":"El-Zayadi","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib28","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0041-1345(98)00554-5","article-title":"Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin","volume":"30","author":"Gotz","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/S1089-3261(05)70240-3_bib29","series-title":"Clinical Applications of Ribavirin","first-page":"39","article-title":"Combined interferon-alpha2, rimantidine hydrochloride and ribavirin inhibition of influenza virus replication in vitro","author":"Hayden","year":"1984"},{"key":"10.1016\/S1089-3261(05)70240-3_bib30","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep.510270431","article-title":"Re-treatment of chronic hepatitis C with consensus interferon","volume":"27","author":"Heathcote","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib31","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/hep.510270630","article-title":"Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes","volume":"27","author":"Ilyin","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0016-5085(93)90727-T","article-title":"A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C","volume":"105","author":"Kakumu","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.1998.00836.x","article-title":"Ribavirin and interferon alfa-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions","volume":"46","author":"Khakoo","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib34","doi-asserted-by":"crossref","first-page":"A1271","DOI":"10.1016\/S0016-5085(98)85161-5","article-title":"Pilot study of Intron-A and ribavirin vs Intron-A and amantidine in interferon non-responders with chronic hepatitis C [abstract]","volume":"114","author":"Khalili","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib35","first-page":"375A","article-title":"Interim results of the NYNEST interferon\u2013ribavirin retreatment trial in chronic hepatitis C non-responders [abstract]","volume":"28","author":"Krawitt","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib36","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/gast.1996.v111.pm8898645","article-title":"Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C","volume":"111","author":"Lai","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/hep.510260130","article-title":"Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa","volume":"26","author":"Lam","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0676.1994.tb00093.x","article-title":"Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon","volume":"14","author":"Marcellin","year":"1994","journal-title":"Liver"},{"key":"10.1016\/S1089-3261(05)70240-3_bib39","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/167.3.780","article-title":"Retreatment with recombinant interferon-alfa in patients with chronic hepatitis C","volume":"167","author":"Marcellin","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/S1089-3261(05)70240-3_bib40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1006\/cyto.1997.0333","article-title":"Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients","volume":"10","author":"Martin","year":"1998","journal-title":"Cytokine"},{"key":"10.1016\/S1089-3261(05)70240-3_bib41","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep.1840220406","article-title":"Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C","volume":"22","author":"Martinot-Peignoux","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib42","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.510270333","article-title":"Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity","volume":"27","author":"Mathurin","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib43","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: Results of a U.S. multicenter randomized controlled study","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S1089-3261(05)70240-3_bib44","first-page":"286A","article-title":"Interferon alfa-2b and ribavirin in patients with chronic hepatitis C without sustained response to prior interferon responders [abstract]","volume":"28","author":"Min","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib45","first-page":"476A","article-title":"Interferon plus ribavirin in interferon non-responders or relapsing chronic hepatitis C patients: End-of-treatment response and sustained response at third follow-up month responders [abstract]","volume":"28","author":"Moreno-Monteagudo","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib46","first-page":"478A","article-title":"Combination therapy with interferon and ribavirin induces response in patients with chronic hepatitis C non-responders to interferon responders [abstract]","volume":"28","author":"Moussalli","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib47","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.4049\/jimmunol.160.7.3487","article-title":"Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, and procoagulant activity and preserves TH1 cytokine production, but inhibits TH2 cytokine response","volume":"160","author":"Ning","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib48","first-page":"367A","article-title":"Early changes in HCV RNA kinetics with interferon and ribavirin compared to interferon alone suggest an additive antiviral effect with ribavirin [abstract]","volume":"26","author":"Nyberg","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib49","doi-asserted-by":"crossref","first-page":"A1316","DOI":"10.1016\/S0016-5085(98)85342-0","article-title":"Amantidine monotherapy in patients with chronic hepatitis C [abstract]","volume":"114","author":"Olmeda","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib50","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/clinids\/12.6.1139","article-title":"Molecular action of ribavirin","volume":"12","author":"Patterson","year":"1990","journal-title":"Reviews of Infectious Diseases"},{"key":"10.1016\/S1089-3261(05)70240-3_bib51","first-page":"228A","article-title":"Effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus genotype 1b replication kinetics and clearance [abstract]","volume":"28","author":"Pawlotsky","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib52","first-page":"453","article-title":"The interferon system in acute and chronic viral hepatitis","volume":"vol 8","author":"Peters","year":"1986"},{"key":"10.1016\/S1089-3261(05)70240-3_bib53","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1074\/jbc.272.4.2312","article-title":"Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling","volume":"272","author":"Pettit","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/S1089-3261(05)70240-3_bib54","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1046\/j.1523-1755.1998.00113.x","article-title":"Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients","volume":"54","author":"Pham","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/S1089-3261(05)70240-3_bib55","first-page":"273A","article-title":"Two year interferon retreatment may induce a sustained response in relapsing patients with chronic hepatitis [abstract]","volume":"24","author":"Picciotti","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib56","first-page":"356A","article-title":"Ribavirin-interferon versus interferon alone in non-responders to \u03b1-IFN in chronic hepatitis [abstract]","volume":"24","author":"Pol","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib57","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","article-title":"A comparison of three interferon alfa-2b regimens for the long term treatment of chronic non-A, non-B hepatitis","volume":"332","author":"Poynard","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/S1089-3261(05)70240-3_bib58","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.510240405","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration","volume":"24","author":"Poynard","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib59","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomized trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S1089-3261(05)70240-3_bib60","first-page":"497A","article-title":"Impact of interferon and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C [abstract]","volume":"28","author":"Poynard","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib61","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/S1089-3261(05)70240-3_bib62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","article-title":"Alfa-interferon and ribavirin versus alfa-interferon alone as therapy for chronic hepatitis C\u2013a randomized, double, blind, placebo-controlled study","volume":"351","author":"Reichard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S1089-3261(05)70240-3_bib63","first-page":"215A","article-title":"Analysis of the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa and ribavirin [abstract]","volume":"26","author":"Sarrazin","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib64","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0168-8278(97)80103-1","article-title":"Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers","volume":"26","author":"Schalm","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jmv.1890460110","article-title":"Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone","volume":"46","author":"Schvarcz","year":"1995","journal-title":"J Med Virol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib66","first-page":"505","article-title":"Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic hepatitis C not responding to alpha-interferon alone","volume":"28","author":"Scotto","year":"1996","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib67","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/gast.1996.v110.pm8536870","article-title":"Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity","volume":"110","author":"Serfaty","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib68","doi-asserted-by":"crossref","first-page":"586","DOI":"10.7326\/0003-4819-122-8-199504150-00005","article-title":"Hepatic hepatitis C virus RNA as a predictor of long term response to interferon-\u03b1 therapy","volume":"122","author":"Shindo","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/S1089-3261(05)70240-3_bib69","first-page":"287A","article-title":"High response rate to interferon\/ribavirin treatment in HCV relapsers but not in non-responders [abstract]","volume":"28","author":"Sjogren","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib70","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1023\/A:1018857314351","article-title":"Treatment of chronic hepatitis C with amantadine","volume":"42","author":"Smith","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/S1089-3261(05)70240-3_bib71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hep.510280208","article-title":"Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial","volume":"28","author":"Sostegni","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib72","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0168-8278(91)90814-R","article-title":"Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomized clinical trials","volume":"13","author":"Tin\u00e9","year":"1991","journal-title":"J Hepatol"},{"key":"10.1016\/S1089-3261(05)70240-3_bib73","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.510300203","article-title":"Health-related quality of life in chronic hepatitis C: Impact of treatment and treatment response","volume":"30","author":"Ware","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib74","first-page":"288A","article-title":"Erythropoietin use for ribavirin\/interferon induced anemia in patients with hepatitis [abstract]","volume":"28","author":"Weisz","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib75","first-page":"591A","article-title":"Cost-effectiveness of ribavirin and interferon alfa-2b after interferon relapse in chronic hepatitis C [abstract]","volume":"28","author":"Wong","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib76","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0016-5085(92)91129-R","article-title":"Recurrent and acquired hepatitis C viral infection in liver transplant recipients","volume":"103","author":"Wright","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib77","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.510230607","article-title":"The long-term pathological evolution of chronic hepatitis C","volume":"23","author":"Yano","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib78","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/hep.510280132","article-title":"Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover","volume":"28","author":"Zeuzem","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S1089-3261(05)70240-3_bib79","first-page":"374A","article-title":"Treatment of refractory symptomatic HCV-related mixed cryoglobulinemia with ribavirin and interferon alfa [abstract]","volume":"28","author":"Zuckerman","year":"1998","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326105702403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326105702403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T04:51:02Z","timestamp":1706331062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326105702403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,11]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,11]]}},"alternative-id":["S1089326105702403"],"URL":"https:\/\/doi.org\/10.1016\/s1089-3261(05)70240-3","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[1999,11]]}}}